niacinamide and GDC-0623

niacinamide has been researched along with GDC-0623 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, DJ; Belvin, M; Chan, J; Chen, H; Friedman, LS; Haling, JR; Hatzivassiliou, G; Heald, R; Hewitt, JF; Hoeflich, KP; Ludlam, MJ; Luoh, SM; Malek, S; Merchant, M; Orr, C; Peck, A; Price, S; Song, K; Ultsch, M; Wiesmann, C; Zak, M	1
Baillie, TA; Cyrus Khojasteh, S; Dalvie, D; Rietjens, IM	1
Cho, E; Choi, KM; Chung, YH; Han, EH; Kang, M; Kim, B; Kim, E; Kim, JY; Shin, JH	1

Reviews

1 review(s) available for niacinamide and GDC-0623

Article	Year
Biotransformation and bioactivation reactions - 2015 literature highlights. Drug metabolism reviews, 2016, Volume: 48, Issue:2 Topics: Acetaminophen; Allylbenzene Derivatives; Aniline Compounds; Animals; Anisoles; Benzbromarone; Biotransformation; Humans; Imidazoles; Niacinamide; Nitroimidazoles; Nitrosamines; Oxazoles; Oxazolidinones; Peroxides; Pyrazines; Pyrazoles; Pyridazines; Pyridines; Pyridones; Pyrimidinones; Thiophenes; Triazoles	2016

Article

Year

Biotransformation and bioactivation reactions - 2015 literature highlights.

Drug metabolism reviews, 2016, Volume: 48, Issue:2

Topics: Acetaminophen; Allylbenzene Derivatives; Aniline Compounds; Animals; Anisoles; Benzbromarone; Biotransformation; Humans; Imidazoles; Niacinamide; Nitroimidazoles; Nitrosamines; Oxazoles; Oxazolidinones; Peroxides; Pyrazines; Pyrazoles; Pyridazines; Pyridines; Pyridones; Pyrimidinones; Thiophenes; Triazoles

2016

Other Studies

2 other study(ies) available for niacinamide and GDC-0623

Article	Year
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013, Sep-12, Volume: 501, Issue:7466 Topics: Allosteric Regulation; Azetidines; Cell Survival; Clinical Trials as Topic; Crystallography, X-Ray; Enzyme Activation; Feedback, Physiological; Genes, ras; HCT116 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Neoplasms; Niacinamide; Oncogene Protein p21(ras); Phosphorylation; Phosphoserine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf	2013
Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer. Biochemical and biophysical research communications, 2018, 12-09, Volume: 507, Issue:1-4 Topics: Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Invasiveness; Niacinamide; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinolines; Stomach Neoplasms; TOR Serine-Threonine Kinases	2018

Article

Year

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

Nature, 2013, Sep-12, Volume: 501, Issue:7466

Topics: Allosteric Regulation; Azetidines; Cell Survival; Clinical Trials as Topic; Crystallography, X-Ray; Enzyme Activation; Feedback, Physiological; Genes, ras; HCT116 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Neoplasms; Niacinamide; Oncogene Protein p21(ras); Phosphorylation; Phosphoserine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf

2013

Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.

Biochemical and biophysical research communications, 2018, 12-09, Volume: 507, Issue:1-4

Topics: Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Invasiveness; Niacinamide; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinolines; Stomach Neoplasms; TOR Serine-Threonine Kinases

2018